Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia

European Journal of Endocrinology

Volumn 150, Issue 4, 2004, Pages 591-603

  Crescioli, C ^a   Ferruzzi, P ^a   Caporali, A ^b   Scaltriti, M ^c   Bettuzzi, S ^b   Mancina, R ^a   Gelmini, S ^a   Serio, M ^a   Villari, D ^a   Vannelli, G B ^a   Colli, E ^d   Adorini, L ^d   Maggi, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d BioXell SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALPHA FLUORO 25 HYDROXY 16,23E DIENE 26,27 BISHOMO 20 EPI CHOLECALCIFEROL; ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; BIOLOGICAL MARKER; BXL 628; CALCITRIOL DERIVATIVE; CLUSTERIN; DNA FRAGMENT; FINASTERIDE; GROWTH FACTOR; LUCIFERASE; METRIBOLONE; PLACEBO; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TESTOSTERONE ENANTATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALCIUM BLOOD LEVEL; CASTRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS FUNCTION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VENTRAL LOBE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; TESTIS FUNCTION; TISSUE HOMOGENATE;

ANIMALS; CALCITRIOL; CELL DIVISION; CLINICAL TRIALS, PHASE II; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; ORCHIECTOMY; PROSTATE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED;

EID: 2342469355     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500591     Document Type: Article

References (37)

1. Johnson CS. Hershberger PA & Trump DL. Vitamin D-related therapies in prostate cancer. Cancer Metastasis Review 2002 21 147-158.
2. Osborne JE & Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? British Journal of Dermatology 2002 147 197-213.
3. Colston KW & Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocrine-Related Cancer 2002 9 45-59.
4. Adorini L. 1,25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation. Current Opinion in Investigational Drugs 2002 3 1458-1463.
5. Welsh J, Wietzke JA, Zinser G M, Smyczek S, Romu S, Tribble E et al. Impact of the vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. Journal of Steroid Biochemistry and Molecular Biology 2002 83 85-92.
6. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA & Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Research 1994 54 805-810.
7. Kivineva M, Blauer M, Syvala H. Tammela T & Tuohimaa P. Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. Journal of Steroid Biochemistry and Molecular Biology 1998 66 121-127.
8. Crescioli C, Maggi M, Vannelli GB, Luconi M, Salerno R, Barni T et al. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. Journal of Clinical Endocrinology and Metabolism 2000 85 2576-2583.
9. Malluche HH, Mawad H & Koszewski NJ. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney International 2002 62 367-374.
10. Crescioli C, Villari D, Forti G, Ferruzzi P, Petrone L, Vannelli GB et al. Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D(3) analogue. Molecular and Cellular Endocrinology 2002 198 69-75.
11. Crescioli C, Ferruzzi P, Caporali A, Mancina R, Comerci A, Muratori M et al. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology 2003 144 3046-3057.
12. Steers W. 5alpha-reductase activity in the prostate. Urology 2001 58 17-24.
13. Thigpen AE, Cala KM & Russell DW. Characterization of Chinese hamster ovary cell lines expressing human steroid 5 alpha-reductase isozymes. Journal of Biological Chemistry 1993 268 17404-17412.
14. Bonaccorsi L, Carloni V, Muratori M, Salvadori A, Giannini A, Carini M et al. Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology 2000 141 3172-3182.
15. Guarna A, Machetti F, Occhiato EG, Scarpi D, Comerci A, Danza G et al. Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1. Journal of Medicinal Chemistry 2000 43 3718-3735.
16. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976 72 248-254.
17. Pazzagli M, Devine JH, Peterson DO & Baldwin TO. Use of bacterial and firefly luciferases as reporter genes in DEAE-dextran-mediated transfection of mammalian cells. Analytical Biochemistry 1992 204 315-323.
18. Bettuzzi S, Hiipakka RA, Gilna P & Liao S. Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochemical Journal 1989 257 293-296.
19. Marinelli M, Quaglino D, Bettuzzi S, Strocchi P, Davalli P & Corti A. Increased levels of clusterin mRNA in the ventral prostate of the aging rat are associated to increases in cuboidal (atrophic) cell population and not to changes in apoptotic activity. Biochemistry and Cell Biology 1994 72 515- 521.
20. Astancolle S, Guidetti G, Pinna C, Corti A & Bettuzzi S. Increased levels of clusterin (SGP-2) mRNA and protein accompany rat ventral prostate involution following finasteride treatment. Journal of Endocrinology 2000 167 197-204.
21. Munson PJ & Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Analytical Biochemistry 1980 107 220-239.
22. De Lean A, Munson PJ & Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. American Journal of Physiology 1978 235 E97-E102.
23. Bettuzzi S, Scorcioni F, Astancolle S, Davalli P, Scaltriti M & Corti A. Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalised human prostate epithelial cells by slowing down cell cycle progression. Oncogene 2002 21 4328-4334.
24. Zhou W, Janulis L, Park II & Lee C. A novel anti-proliferative property of clusterin in prostate cancer cells. Life Science 2002 72 11-21.
25. Bettuzzi S, Zoli M, Ferraguti F, Ingletti MC, Agnati LF & Corti A. Regional and cellular distribution within the rat prostate of two mRNA species undergoing opposite regulation by androgens. Journal of Endocrinology 1992 132 361-367.
26. Leger JG, Montpetit ML & Tenniswood MP. Characterization and cloning of androgen-repressed mRNAs from rat ventral prostate. Biochemical and Biophysical Research Communications 1987 147 196-203.
27. Filippi S, Luconi M, Granchi S, Vignozzi L, Bettuzzi S, Tozzi P et al. Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis. Endocrinology 2002 143 4271-4280.
28. Souverein PC, Erkens JA, de la Rosette JJ, Leufkens HG & Herings RM. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. European Urology 2003 43 528-534.
29. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. New England Journal of Medicine 1998 338 557-563.
30. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. New England Journal of Medicine 2003 349 215-224.
31. Kassabian VS. Sexual function in patients treated for benign prostatic hyperplasia. Lancet 2003 361 60-62.
32. Scardino PT. The prevention of prostate cancer. The dilemma continues. New England Journal of Medicine 2003 349 297-299.
33. Leskov KS, Klokov DY, Li J, Kinsella TJ & Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. Journal of Biological Chemistry 2003 278 11590-11600.
34. Crescioli C, Maggi M, Luconi M, Vannelli GB, Salerno R, Sinisi AA et al. Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. Prostate 2002 50 15-26.
35. Cordero JB, Cozzolino M, Lu Y, Vidal M, Slatopolsky E, Stahl PD et al. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. Journal of Biological Chemistry 2002 277 38965-38971.
36. Peleg S. Uskokovic MR, Ahene A, Vickery B & Avnur Z. Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog RO-26-9228 in osteoporoic rats. Endocrinology 2002 143 1625-1636.
37. 3. Journal of Cellular Biochemistry 2003 88 267-273.